CN101820884B - 用于治疗轻度认知缺损的吩噻嗪化合物 - Google Patents

用于治疗轻度认知缺损的吩噻嗪化合物 Download PDF

Info

Publication number
CN101820884B
CN101820884B CN2008801031955A CN200880103195A CN101820884B CN 101820884 B CN101820884 B CN 101820884B CN 2008801031955 A CN2008801031955 A CN 2008801031955A CN 200880103195 A CN200880103195 A CN 200880103195A CN 101820884 B CN101820884 B CN 101820884B
Authority
CN
China
Prior art keywords
mtc
treatment
scopolamine
memory
rivastigmine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801031955A
Other languages
English (en)
Chinese (zh)
Other versions
CN101820884A (zh
Inventor
克劳德·M·威希克
多米尼克·V·哈巴兰
杰诺特·里德尔
塞雷娜·戴亚纳
伊丽莎白·A·戈特曼
戴蒙·J·威希克
艾利森·D·默里
罗杰·T·斯塔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN101820884A publication Critical patent/CN101820884A/zh
Application granted granted Critical
Publication of CN101820884B publication Critical patent/CN101820884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801031955A 2007-06-19 2008-06-17 用于治疗轻度认知缺损的吩噻嗪化合物 Active CN101820884B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (2)

Publication Number Publication Date
CN101820884A CN101820884A (zh) 2010-09-01
CN101820884B true CN101820884B (zh) 2013-08-28

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801031955A Active CN101820884B (zh) 2007-06-19 2008-06-17 用于治疗轻度认知缺损的吩噻嗪化合物

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
KR101888713B1 (ko) * 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
EP3686181B1 (en) * 2013-01-30 2024-07-17 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) * 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
DK2853293T3 (en) * 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
MY162313A (en) * 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats》;Narriman Lee Callaway,Penny D.Riha,Kathrym M.Wrubel.et.al;《Neuroscience Letters》;20021031;第332卷(第2期);83-86 *

Also Published As

Publication number Publication date
HUE045460T2 (hu) 2019-12-30
HRP20191513T1 (hr) 2019-11-29
JP5725605B2 (ja) 2015-05-27
US9211294B2 (en) 2015-12-15
SI2167095T1 (sl) 2019-09-30
MY177001A (en) 2020-09-01
PL2167095T3 (pl) 2019-11-29
DK2167095T3 (da) 2019-07-29
EP2167095B1 (en) 2019-05-29
JP2010530403A (ja) 2010-09-09
WO2008155533A2 (en) 2008-12-24
CA2690746A1 (en) 2008-12-24
WO2008155533A3 (en) 2009-02-19
ES2739546T3 (es) 2020-01-31
AU2008265045B2 (en) 2014-02-27
PT2167095T (pt) 2019-08-06
CN101820884A (zh) 2010-09-01
AU2008265045A1 (en) 2008-12-24
EP2167095A2 (en) 2010-03-31
US20100184752A1 (en) 2010-07-22
CA2690746C (en) 2018-01-02
BRPI0813670A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
EP2167095B1 (en) Phenothiazine compounds for treating mild cognitive impairment
KR102654569B1 (ko) 외상 후 스트레스 장애의 치료를 위한 제제
CN107810002B (zh) 左乙拉西坦的延时释放药物组合物
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
ES2881081T3 (es) Procedimientos y composiciones para mejorar la función cognitiva
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN114072945A (zh) 用于治疗精神障碍、行为障碍、认知障碍的新型药物组合物和方法
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
US10736894B2 (en) Methods of treating developmental syndromes with PDE10A inhibitors
EP2286810A1 (en) Pharmaceutical composition for treatment of fibromyalgia
Jillani et al. Atomoxetine for the treatment of ADHD in incarcerated adolescents
JP2018505899A (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
WO2021053076A1 (en) Combination therapy with vildagliptin and metformin
JP2019519480A (ja) パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
ES2747993T3 (es) Composiciones farmacéuticas de liberación prolongada de levetiracetam
Yoon et al. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial
HK40052880A (en) Extended release pharmaceutical compositions of levetiracetam
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
HK1252154B (en) Extended release pharmaceutical compositions of levetiracetam

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant